Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry
Circulation · 04.07.2023 · 148 (1) · 35-46
DOI: 10.1161/circulationaha.123.064959 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 04.07.2023. Verfasst von Mohit K Turagam und 50 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, NY (M.K.T., V.Y.R.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Atrial Flutter, Catheter Ablation, Pulmonary Veins. Die Arbeit wurde bisher 396-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background
Pulsed field ablation is a novel nonthermal cardiac ablation modality using ultra-rapid electrical pulses to cause cell death by a mechanism of irreversible electroporation. Unlike the traditional ablation energy sources, pulsed field ablation has demonstrated significant preferentiality to myocardial tissue ablation, and thus avoids certain thermally mediated complications. However, its safety and effectiveness remain unknown in usual clinical care.
Methods
MANIFEST-PF (Multi-National Survey on the Methods, Efficacy, and Safety on the Post-Approval Clinical Use of Pulsed Field Ablation) is a retrospective, multinational, patient-level registry wherein patients at each center were prospectively included in their respective center registries. The registry included all patients undergoing postapproval treatment with a multielectrode 5-spline pulsed field ablation catheter to treat atrial fibrillation (AF) between March 1, 2021, and May 30, 2022. The primary effectiveness outcome was freedom from clinical documented atrial arrhythmia (AF/atrial flutter/atrial tachycardia) of ≥30 seconds on the basis of electrocardiographic data after a 3-month blanking period (on or off antiarrhythmic drugs). Safety outcomes included the composite of acute (7 days) major adverse events.
Results
At 24 European centers (77 operators) pulsed field ablation was performed in 1568 patients with AF: age 64.5±11.5 years, female 35%, paroxysmal/persistent AF 65%/32%, CHA 2 DS 2 -VASc 2.2±1.6, median left ventricular ejection fraction 60%, and left atrial diameter 42 mm. Pulmonary vein isolation was achieved in 99.2% of patients. After a median (interquartile range) follow-up of 367 (289–421) days, the 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia was 78.1% (95% CI, 76.0%–80.0%); clinical effectiveness was more common in patients with paroxysmal AF versus persistent AF (81.6% versus 71.5%; P =0.001). Acute major adverse events occurred in 1.9% of patients.
Conclusions
In this large observational registry of the postapproval clinical use of pulsed field technology to treat AF, catheter ablation using pulsed field energy was clinically effective in 78% of patients with AF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, New York, NY (M.K.T., V.Y.R.).
- Cardiology Department, Na Homolce Hospital, Homolka Hospital, Prague, Czechia (P.N., M.F., J.P., V.Y.R.).
- MVZ CCB Frankfurt und Main-Taunus GbR, Frankfurt, Germany (B.S., J.C.).
- Inselspital-Bern University Hospital, University of Bern, Switzerland (T.R., L.R., T.K.).
- Department of Medicine, Witten/Herdecke University, Germany (K. Neven, A.F., G.R.).
- Department of Electrophysiology, Alfried Krupp Hospital, Essen, Germany (K. Neven, A.F.).
ORCID-Profile: Mohit K Turagam, Petr Neuzil, Boris Schmidt, Tobias Reichlin, Philippe Maury, Ante Anic, Frédéric Anselme, Serge Boveda, Tom Deneke, Roland Tilz, Reza Wakili, Daniel Steven, Josef Kautzner, Johan Vijgen, Pierre Jais, Julian Chun, Laurent Roten, Anna Füting, Marc D Lemoine, Bart A Mulder, Zrinka Jurisic, Corentin Chaumont, Raquel Adeliño, Karin Nentwich, Melanie Gunawardene, Christian-Hendrik Heeger, Martin Manninger, Petr Peichl, Pieter Koopman, Nicolas Derval, Thomas Kueffer, Vivek Y Reddy
Zitieren
APA
Turagam, M. K., Neuzil, P., Schmidt, B., Reichlin, T., Neven, K., Metzner, A., Hansen, J., Blaauw, Y., Maury, P., Arentz, T., Sommer, P., Anic, A., Anselme, F., Boveda, S., Deneke, T., Willems, S., van der Voort, P., Tilz, R., Funasako, M., …, & Reddy, V. Y. (2023). Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry. Circulation, 148(1), 35-46. https://doi.org/10.1161/circulationaha.123.064959
Vancouver
Turagam MK, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry. Circulation. 2023;148(1):35-46. doi:10.1161/circulationaha.123.064959
BibTeX
@article{Turagam2023,
author = {Turagam, Mohit K and Neuzil, Petr and Schmidt, Boris and Reichlin, Tobias and Neven, Kars and Metzner, Andreas and Hansen, Jim and Blaauw, Yuri and Maury, Philippe and Arentz, Thomas and Sommer, Philipp and Anic, Ante and Anselme, Frédéric and Boveda, Serge and Deneke, Tom and Willems, Stephan and van der Voort, Pepijn and Tilz, Roland and Funasako, Moritoshi and Scherr, Daniel and Wakili, Reza and Steven, Daniel and Kautzner, Josef and Vijgen, Johan and Jais, Pierre and Petru, Jan and Chun, Julian and Roten, Laurent and Füting, Anna and Lemoine, Marc D and Ruwald, Martin and Mulder, Bart A and Rollin, Anne and Lehrmann, Heiko and Fink, Thomas and Jurisic, Zrinka and Chaumont, Corentin and Adeliño, Raquel and Nentwich, Karin and Gunawardene, Melanie and Ouss, Alexandre and Heeger, Christian-Hendrik and Manninger, Martin and Bohnen, Jan-Eric and Sultan, Arian and Peichl, Petr and Koopman, Pieter and Derval, Nicolas and Kueffer, Thomas and Rahe, Gilbert and Reddy, Vivek Y},
title = {Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry},
journal = {Circulation},
year = {2023},
volume = {148},
number = {1},
pages = {35--46},
doi = {10.1161/circulationaha.123.064959}
}
EUVIMED